1369855-94-6

Upstream product

• 75-30-9 2-iodo-propane 
• 10323-39-4 4-bromo-2-tert-butylphenol 
• 88-18-6 2-tert-Butylphenol 

Downstream Products

• 1378367-41-9 2-(3-(tert-butyl)-4-isopropoxyphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 1378368-34-3 1-(4-(3-(tert-butyl)-4-isopropoxyphenyl)pyrimidin-2-yl)piperidine-4-carbonitrile 
• 1378365-66-2 1-(4-(3-(tert-butyl)-4-isopropoxyphenyl)pyrimidin-2-yl)piperidine-4-carboximidamide 
• 1378368-30-9 (rac)-tert-butyl (1-(4-(4-(3-(tert-butyl)-4-isopropoxyphenyl)pyrimidin-2-yl)phenyl)-2-hydroxyethyl)carbamate 
• 1378365-55-9 2-(4-(1H-imidazol-2-yl)piperidin-1-yl)-4-(3-(tert-butyl)-4-isopropoxyphenyl)pyrimidine 
• 1378365-54-8 C₂₂H₂₈N₆O*ClH 
• 1378368-18-3 5-(4-(3-(tert-butyl)-4-isopropoxyphenyl)pyrimidin-2-yl)picolinonitrile 
• 1378364-74-9 (R)-4-(3-(tert-butyl)-4-isopropoxyphenyl)-2-(3-methylpiperazin-1-yl)pyrimidine 
• 1378367-44-2 4-(3-(tert-butyl)-4-isopropoxyphenyl)-2-chloropyrimidine 
• 1378364-69-2 2-(4-(4-(3-(tert-butyl)-4-isopropoxyphenyl)pyrimidin-2-yl)piperazin-1-yl)ethanol 

Relevant academic research and scientific papers

Desymmetric enantioselective reduction of cyclic 1,3-diketones catalyzed by a recyclable p-chiral phosphinamide organocatalyst

The P-stereogenic phosphinamides are a structurally novel skeletal class which has not been investigated as chiral organocatalysts. However, chiral cyclic 3-hydroxy ketones are widely used as building blocks in the synthesis of natural products and bioactive compounds. However, general and practical methods for the synthesis of such chiral compounds remain underdeveloped. Herein, we demonstrate that the P-stereogenic phosphinamides are powerful organocatalysts for the desymmetric enantioselective reduction of cyclic 1,3-diketones, providing a useful method for the synthesis of chiral cyclic 3-hydroxy ketones. The protocol displays a broad substrate scope that is amenable to a series of cyclic 2,2-disubstituted five- and six-membered 1,3-diketones. The chiral cyclic 3-hydroxy ketone products bearing an all-carbon chiral quaternary center could be obtained with high enantioselectivities (up to 98% ee) and diastereoselectivities (up to 99:1 dr). Most importantly, the reactions could be practically performed on the gram scale and the catalysts could be reused without compromising the catalytic efficiency. Mechanistic studies revealed that an intermediate formed from P-stereogenic phosphinamide and catecholborane is the real catalytically active species. The results disclosed herein bode well for designing and developing other reactions using P-stereogenic phosphinamides as new organocatalysts.

PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF SPHINGOSINE KINASE

The present invention relates to compounds that are useful as inhibitors of the activity of one or more isoforms of sphingosine kinase. Particularly, although not exclusively, the present invention also relates to pharmaceutical compositions comprising th